lems afflicting school-age children, with an estimated worldwide prevalence of 8-12% (Faraone 2003) . Up to 50% of diagnosed children demonstrate clinically significant symptoms and impairment as young adults (Mannuzza 1998; Barkley 2002) , although its persistence is not universally associated with impaired outcomes (Biederman 2005) . The most widely used pharmacological treatment of ADHD is the racemic (50:50) mixture of d-threo-(R,R)-methylphenidate (MPH) and lthreo-(S,S)-MPH isomers (Fig. 1) , a racemic mixture in general clinical use for over 50 years. Depicted in bold within these structures is the phenethylamine pharmacophore of d-MPH shared by the neuronal substrates dopamine (DA) and norepinephrine (NE). Both pharmacodynamic and pharmacokinetic differences between these isomers are well recognized. Although dl-MPH is available as either an immediate-release (IR) or extended-release (ER) formulations (Markowitz et al. 2003) , an enantiopure d-MPH product [d-threo-(R,R)-MPH, dexmethylphenidate] was recently introduced into clinical practice (Keating and Figgit 2002) .
The clinical effectiveness of racemic MPH appears to reside primarily in the d-isomer (see Patrick et al. 2005) . Srinivas et al. (1992) demonstrated similar improvement on sustained attention testing after ADHD subjects were treated with d-MPH or twice the dose of dl-MPH, but not after l-MPH. This study also demonstrated similar pharmacokinetics of d-MPH after the administration of d-MPH as either the pure enantiomeric formulation or as twice the dose of the racemic mixture. The l-MPH isomer of racemic MPH formulations has long been regarded as an inactive or passive component, contributing little to the therapeutic or adverse event profile.
Profound differences between d-and l-MPH metabolism and disposition have consistently been demonstrated in enantiospecific investigations. The presystemic metabolism and metabolic clearance of dl-MPH is an enantioselective process resulting in markedly higher plasma concentrations of d-MPH relative to l-MPH (see Markowitz et al. 2003; Patrick et al. 2005) . In an enantiospecific study of MPH administered intravenously, both isomers exhibited similar distribution characteristics, although the terminal elimination phase of the l-isomer was more rapid (Srinivas et al. 1993 ). In other studies using different oral formulations, the area under the plasma concentration Ϫ time curve (AUC inf ) value for the l-isomer has been reported to reach only approximately 1-15% of that of d-MPH (Ramos et al. 1999; Modi et al. 2000; Patrick et al. 2005) . Although l-MPH exhibits lower oral bioavailability, l- 
d-threo-(2R, 2'R)-methylphenidate l-threo-(2S, 2'S)-methylphenidate
MPH has also been reported to be more stable in human plasma than d-MPH (Srinivas et al. 1991) . Furthermore, radiolabeled l-MPH, or a metabolite with the same chromatographic retention time as an active metabolite of l-MPH, p-hydroxymethylphenidate (Patrick et al. 1981) , was recently reported to be taken up into the brain to a greater extent than d-MPH following oral administration of each isomer to rats or baboons (Ding et al. 2004 ). Interestingly, a recent report describes a normal volunteer study subject identified as a "poor metabolizer" of MPH, exhibiting an extended overall drug halflife and an unprecedented enrichment of l-MPH in plasma relative to d-MPH (Patrick et al. in press 2006) . This abnormal profile is postulated to be due to a genetic deficiency in carboxylesterase activity (CES1A1). However, its frequency of occurrence in the general population cannot be estimated at present. These findings are currently under further investigation by this group. Finally, the recent availability of the dl-MPH transdermal patch reveals much higher plasma concentrations of l-MPH (i.e., values approaching those of d-MPH concentrations in some instances) throughout the day, a profile far different from any existing oral formulation of racemic MPH (Pierce et al. 2005) . Thus, the determination of the pharmacologic profile or contribution of l-MPH compared to d-MPH has now gained greater relevance. A number of preclinical studies have suggested a d-MPH-l-MPH pharmacodynamic interaction associated with the neuropharmacologic effects of racemic MPH. In a recent rodent study, the l-MPH isomer inhibited, in a dose-dependent fashion, the locomotor stimulation by d-MPH, cocaine, or apomorphine in rats (Baldessarini and Cambell 2001) . These results differ from those observed in mice, where l-MPH has been reported to enhance the locomotor stimulatory activity following cocaine (Ding et al. 2002; Ding et al. 2004 ). Davids and co-workers (2002a) (Teo et al. 2003) . When comparing dl-MPH to d-MPH, the inclusion of the l-isomer in dosing regimens enhanced the degree of repetitive pawing, dilated pupils, and aggressive behavior observed in rats and head-bobbing and hyperpnea in rabbits (Teo et al. 2003) .
In view of the reported differences between d-and l-MPH activities, the present in vitro study was carried out to assess further the individual affinity of MPH isomers, as well as the racemic mixture, in a broad array of receptor binding, ion channel, transporter, and cellular assays of interest in central nervous system (CNS) pharmacology inclusive of, and beyond the typical monoamine [i.e., NE, DA, and serotonin (5-HT)] neurotransmitters assays carried out to date. This study focuses on differences in MPH isomer affinity for pharmacologically relevant sites that may be pertinent to enantiospecific therapeutic and/or adverse effect profiles associated with each isomer or racemic MPH.
MATERIALS AND METHODS

Chemical compounds
, and dl-threo-methylphenidate (dl-MPH) were purchased in their hydrochloride salt forms from Sigma-Aldrich (St. Louis, MO).
Receptor binding, ion channel, and transporter assays
All receptor binding assays, ion channel assays, transporter studies, and cellular uptake/ release assays were performed by CEREP (Celle l'Evescault, France). Unless otherwise specified in the results, all screening studies were initially carried out at concentrations of 10M in duplicate for all three MPH compounds. Concentrations of dl-MPH, d-MPH, and l-MPH were based upon weight, i.e., experiments using the racemate provided 50% less d-MPH than those using the pure enantiomer. If greater than 50% displacement of the receptor-specific ligand occurred at this screening concentration, and these values favored one isomer over another or the racemic mixture by Նtwo-fold, further experiments were undertaken assessing multiple concentrations of the compound of interest to generate specific IC 50 values. That is, the concentration of the drug of interest (e.g., MPH racemate or isomers) that competes for 50% of the receptors present (one-half maximal or IC 50 ). The binding equilibrium dissociation constant (K i ) was then calculated from the determined IC 50 value by use of the Cheng-Prusoff equation (Cheng and Prusoff 1973) . Receptor binding affinity is generally quantified utilizing the K i value. In interpreting the K i , the subscript i represents the competitor inhibited radioligand binding. The K i is the concentration of the competing ligand that will bind to one-half the targeted binding sites at equilibrium, in the absence of a specific radioligand or other competitor. If the K i is low, the affinity of the receptor for the inhibitor is high.
Over 100 binding sites for the two individual MPH isomers as well as the racemate were assessed with regard to binding affinity that included approximately 90 CNS receptor binding sites for different biogenic amine and neuropeptide receptors, major ion channels, and major transporters. The individual receptors, ion channels, and transporters assessed as well as origin of cell type are listed in Table 1 . Detailed descriptions of all assays performed may be accessed at the CEREP web site (http://www.cerep.com).
SPECIFIC METHODS
DAT assay
Evaluation of the affinity of compounds for the human dopamine transporter (DAT) in transfected Chinese hamster ovary (CHO) cells was determined in a validated radioligand binding assay. Cell membrane homogenates (25 g of protein) were incubated for 120 minutes at 4°C with 0.5 nM [ 3 H]GBR 12935 in the absence or presence of each test compound in a buffer containing 50 mM of TrisHCl (pH 7.4), 100 mM NaCl, 2 mM EDTA, and 0.1% bovine serum albumin (BSA). Nonspecific binding was determined in the presence of 10 M N- [1-(benzo[b] thien-2-yl-cyclohexyl)] piperidine (BTCP). Following incubation, the samples were filtered under vacuum through glass GF/B filters presoaked with 0.3% PEI and rinsed several times with ice-cold 50 mM Tris-HCl using a 96-sample cell harvester. The filters were then dried and measured for radioactivity in a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint 0, Packard). The results were expressed as a percent inhibition of the control radioligand-specific binding. The standard reference compound was BTCP, which was tested in each experiment at several concentrations to obtain a competition curve from which its IC 50 was calculated.
NET assay
Evaluation of the affinity of compounds for the human norepinephrine transporter (NET) in transfected CHO cells was determined in a radioligand binding assay similar to the procedures described for the DAT assay. Cell membrane homogenates (25 g of protein) were incubated for 90 minutes at 4°C with 1 nM [ 3 H]nisoxetine in the absence or presence of each test compound in a buffer containing 50 mM Tris-HCl (pH 7.4), 120 mM NaCl, and 5 mM KCl. Nonspecific binding was determined in the presence of 1 M of desipramine. Following incubation, the samples were filtered rapidly under vacuum through glass fiber filters (GF/B, Packard), presoaked with 0.3% PEI, and rinsed several times with ice-cold 50 mM Tris-HCl using a 96-sample cell harvester (Unifilter, Packard). The filters were then dried and counted for radioactivity. The results were expressed as a percent inhibition of the control radioligand-specific binding. The standard reference compound was the tricyclic antidepres-sant protriptyline, which was tested in each experiment at several concentrations to generate a competition curve from which its IC 50 is calculated.
Method for determinations of IC 50 values for the human 5-HT 2B and 5-HT 1A receptors
Evaluation of the affinity of d-,l-MPH and the racemate for the agonist site of the human 5-HT 2B receptor was carried out in transfected CHO cells determined in a radioligand binding assay. Cell membrane homogenates (5-10 g of protein) were incubated for 15 minutes at 37°C with 0.2 nM [ 125 I]DOI (1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane) in the absence or presence of each test compound in a buffer containing 50 mM Tris-HCl (pH7.4), 5 mM MgCl 2 , 10 M pargyline, and 0.1% ascorbic acid. Nonspecific binding was determined in the presence of 1 M DOI. Following incubation, the samples were filtered under vacuum through glass fiber filters (GF/B, Packard), presoaked with 0.3% PEI, and rinsed several times with ice-cold 50 mM Tris-HCl using a 96-sample cell harvester (Unifilter, Packard). The filters were dried and then counted for radioactivity. The results were expressed as a percent inhibition of the respective control radioligands for specific binding. The standard reference compound was DOI, which was tested in each experiment to generate a competition curve from which its IC 50 was calculated. ); rat cerebral cortex sodium (Na + ) channel (site 2); rat cerebral cortex chloride (Cl Ϫ ) channel.
METHYLPHENIDATE PHARMACOLOGY AND ADHD 691
Transporter assays
Guinea-pig cerebral cortex adenosine (ADO) transporter, NET, DAT; rat cerebral cortex GABA transporter, rat striatum choline transporter, and SERT. The assays were run at 10 M of each isomer (i.e., d-MPH, l-MPH) as well as racemic (dl-MPH), and the percentage of inhibition is given as the mean of three determinations. All transporter assays were carried out using human transporters in transfected Chinese hamster ovary (CHO) cells.
Cell-based assays
Cellular assays were conducted to provide a functional measure of activity of each isomer and racemate with regard to DA, NE, and 5-HT uptake and release. These assays utilized rat brain synaptosomal preparations.
AT = angiotensin; BZD = benzodiazepine; BB = bombesin; CGRP = calcitonin gene-related peptide; CB = cannabinoid; CCK = cholecystokin; C5a = complement 5 alpha; CRF = corticotropin-releasing factor; GABA = ␥-aminobutyric acid; GAL = galanin; VEGF = vascular endothelial growth factor; I = imidazoline; IP = inositol phosphate; MC = melanocortin; ML = melatonin; NK = neurokinin; NT = neurotensin; Nm = neuromedin; N = nicotinic; ORL = orphanin; PCP = phencyclidine; 5-HT = serotonin; SST = somatostatin; V = vasopressin; K = potassium; Na = sodium; Cl = chloride; ADO = adenosine; NET = norepinephrine transporter; DAT = dopamine transporter; MPH = methylphenidate; CHO = Chinese hamster ovary; DA = dopamine; NE = norepinephrine.
Evaluation of the affinity of all MPH compounds for the human 5-HT 1A receptor was accomplished in a similar manner, but used transfected HEK-293 cells determined in a radioligand binding assay. Cell membrane homogenates (75-100 g of protein) were incubated for 60 min at 22°C with 0.5 nM [ 3 H]8-OH-DPAT ([±]-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene) in the absence or presence of the test compound in a buffer containing 50 mM Tris-HCl (pH 7.4), 10 mM MgSO 4 , 0.5 mM EDTA, and 0.1% ascorbic acid. Nonspecific binding was determined in the presence of 10 M 8-OH-DPAT. Following incubation, the samples were filtered rapidly under vacuum as described above, dried, and then counted for radioactivity. The results were expressed as a percent inhibition of the control radioligand-specific binding. The standard reference compound is 8-OH-DPAT, which was tested in each experiment to calculate an IC 50 , as described above for 5-HT 2B receptors.
Cell-based assays NE uptake:
The evaluation of the effects of the isomers and racemate on NE uptake employed synaptosomes prepared from the rat hypothalamus. The synaptosomes (100 g) were incubated for 20 minutes at 37°C with 0.1 Ci [ 3 H]NE in the absence (control) or presence of the test compound or the reference compound in a buffer containing 118 mM NaCl, 5 mM KCl, 2.5 mM MgSO 4 , 1.2 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 11 mM glucose, 10 M EGTA, and 50 M ascorbic acid (pH 7.4). Basal control activity was determined by incubating the same mixture for 20 minutes at 0°C in the presence of 10 M protriptyline to block the uptake. Following incubation, the samples were filtered and counted, and the results were expressed as a percent inhibition of the control uptake of [ 3 H]NE. The standard inhibitory reference compound was protriptyline, which was tested in each experiment at several concentrations to obtain an inhibition curve from which its IC 50 value was calculated.
DA uptake: The evaluation of the effects of MPH isomers and racemate on DA uptake employed synaptosomes prepared from the rat striatum. The synaptosomes (20 g) were incubated for 15 minutes at 37°C with 0.1 Ci [ 3 H]DA in the absence (control) or presence of the test compound or the reference compound in a buffer containing 118 mM NaCl, 5 mM KCl, 2.5 mM MgSO 4 , 1.2 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 11 mM glucose, 10 M EGTA, and 50 M ascorbic acid (pH 7.4). Basal control activity was determined by incubating the same mixture for 15 minutes at 4°C in the presence of 1 M GBR12909 to block the uptake. After incubation, the samples were filtered and counted, and the results expressed as a percent inhibition of the control uptake of [ 3 H]dopamine. The standard inhibitory reference compound was GBR12909, which was tested in each experiment at several concentrations to obtain an inhibition curve from which its IC 50 value was calculated.
RESULTS
For the vast majority of receptor systems, transporters, and assays assessed (see Table 1 ), no significant binding affinity was apparent for either of the individual MPH isomers or the racemate at the utilized concentration of 10 M, suggesting a remarkably "clean" binding profile for MPH in general. The concentration of MPH employed in this initial screening study (i.e., 10 M) is widely used in general high-throughput pharmacological screening procedures and is accepted to be sufficiently high in pharmacological screening of this nature so that if any significant binding affinity would be a characteristic of a given compound, it would be apparent under the assay conditions employed.
The specific results of the in vitro screening for receptor binding for d-, l-, and dl-MPH in which significant binding occurred (i.e., Ն50% displacement of the specific receptor ligand) are presented in Table 2 . There was measurable, albeit relatively weak, binding affinity of both MPH isomers and the racemate to a number of muscarinic receptors including M 1 , M 2 , M 3 , M 4 , and M 5 . Generally, binding affinity was similar between the two isomers and racemate, although binding of d-MPH appeared to be significantly weaker than that of l-MPH for the M 2 muscarinic receptor ( (Table 2 ). For each of these sites, the binding was largely attributable to d-MPH rather than l-MPH. Although almost all previous investigations, including the present study, have found little interaction of MPH with the 5-HT transporter (SERT), the possibility of direct serotonergic agonist or antagonist activity at these specific 5-HT receptors was of particular interest. Accordingly, further studies were undertaken to generate IC 50 and K i values for the 5-HT 1A and 5-HT 2B (agonist site) receptor subtypes. These results are presented in Table 3 . The data revealed IC 50s and K i values of below 10 M for d-MPH and above 100 M for l-MPH for both serotonergic sites.
Binding to the cellular monoamine transporters of the most prominent neurotransmitters [NE, DA, 5-HT, ␥-aminobutyric acid (GABA), and choline] revealed that overall activity was the greatest for the NET and DAT while being negligible for GABA, choline, and 5-HT transporters. Furthermore, MPH isomers exhibited stereoselectivity in transporter binding with greater affinity noted for d-MPH relative to l-MPH at both the NET and DAT sites (Table 4 ; GABA and choline data not shown).
The results of cellular assays are presented in Table 5 and reveal that cellular uptake inhibition occurred and was more prominent with d-MPH than l-MPH for both NE and DA. However, 5-HT uptake did not differ significantly between the three test compounds and was not a prominent effect relative to the aforementioned effects upon NE or DA.
DISCUSSION
This study presents the results of a comprehensive in vitro pharmacological assessment of affinity with receptors, transporters, and ion channels pertinent to CNS activity. Racemic MPH was compared against the separate dand l-MPH isomers in all assays. Contemporary high-throughout pharmacological screen- a Concentrations of dl-MPH, d-MPH, and l-MPH were weight-based, i.e., experiments using the racemate provided 50% less d-MPH than those using the pure isomer.
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b Further testing to determine specific IC50 values was carried out. 4.9 4.7 >100 >100 13 13
IC 50 = one-half maximal drug concentration; K i = dissociation constant; 5-HT = serotonin.
a Concentrations of dl-MPH, d-MPH, and l-MPH were weight-based, i.e., experiments using the racemate provided 50% less d-MPH than those using the pure isomer.
ing techniques, generally used to assess novel drug entities or lead therapeutic compounds during the preclinical development phase (Entzeroth et al. 2000) were applied to racemic MPH and its respective isomers. Additionally, beyond the standard binding affinity assessments at the major monoamine transporters (e.g., DAT, NET) where MPH and other psychostimulants are widely believed to exert their primary pharmacological activity, this investigation was extended to include the assessment of drug binding affinity to a wide array of CNS receptors, ion channels, and transporters (Table 1) in an effort to characterize these compounds better. Such an enantiospecific study can provide preliminary evidence of pharmacologic activity heretofore unrecognized as a component of MPH therapeutic action and/or side effects. Additionally, cellular uptake and release studies were carried out assessing MPH effects on DA, NE, and 5-HT. It must be emphasized that these data are preliminary in terms of representing binding affinities only and do not discriminate between agonist or antagonist activity. Thus, the ability to speculate on the potential clinical implications of these findings is highly limited.
From the IC 50 data of NE and DA uptake (Table 5) , it was revealed that the most potent in vitro pharmacologic effect of MPH, considered as either single enantiomers or as the racemate, was on inhibition of the NET. This differential binding affinity of d-MPH versus l-MPH at the major amine transporters appears to replicate the findings of several others that have been reported previously (Patrick et al. 1987; Pan et al. 1994; Wall et al. 1995) . In microdialysis studies in rats, both MPH and the NE reuptake inhibitor atomoxetine have been found to increase significantly the rate of NE release in the prefrontal cortex in a dose-dependent fashion (Bymaster et al. 2002) . The d-MPH isomer was found to be 13.8 times more potent at the NET relative to the l-MPH isomer in the present study (0.47/0.034 = 13.8). Nu-694 MARKOWITZ ET AL. Arnsten and Dudley (2005) , using a rat model, reported that some of the beneficial effects of racemic MPH on cognition were attributed to a facilitation of NE-and DA-mediated stimulation of ␣ 2 adrenoreceptors and D 1 receptors, respectively, in the prefrontal cortex.
Although the present study did not find any direct binding affinity at ␣ 2 or D 1 receptors by any MPH isomer, the work of Arnsten and Dudley highlights the fact that indirect effects of MPH are clearly possible at these and other receptors via modulation of endogenous monoamines. ADHD has been described as a disorder with a significant noradrenergic component (Biederman et al. 1999; Bymaster et al. 2002; Pliszka 2005) , and, interestingly, Yang and associates (2004) recently reported an association between response to dl-MPH and a genetic polymorphism associated with the NET.
The 5-HT 1A receptors are localized dendritically as inhibitory autoreceptors on serotonergic cell bodies of the median raphe nucleus, which predominantly innervates the dorsal hippocampus, septum, and hypothalamus, as well as the dorsal raphe nucleus providing input into the frontal cortex, ventral hippocampus, and striatum (Barnes and Sharpe 1999) . Furthermore, postsynaptic 5-HT 1A sites are abundant in the frontal cortex, hippocampus, and other corticolimbic structures. Accordingly, both pre-and postsynaptic 5-HT 1A receptors are likely to contribute to the modulation of mood, cognition, and motor behavior (Barnes and Sharpe 1999) . In addition, the 5-HT 1A receptors are known to modulate dopaminergic activity directly and the 5-HT 1A agonist 8-OH-DPAT has been shown to reverse certain MPH-induced stereotyped gnawing (Kleven et al. 1996) . At present, relative to 5-HT 1A , much less is known about the 5-HT 2B receptor, its brain distribution, or general neuropharmacology (Barnes and Sharpe 1999) .
The finding of modest, yet stereoselective, binding of d-MPH to the 5-HT 1A and 5-HT 2B receptor sites was not anticipated at the outset of this study. This finding is of interest given the recognized role of serotonergic neurotransmission in many psychiatric disorders (Naughton et al. 2000; Huang et al. 2004 ) as well as associations between 5-HT and ADHD (Faraone 2005) . Additionally, there is some data indicating that psychostimulant medications may directly or indirectly influence 5-HT (Gainetdinov et al. 1999; Quist 2001) . However, it must be emphasized that the nature of the current binding affinity studies preclude distinguishing between agonist, antagonist, partial agonist, or mixed agonist-antagonist activity at either 5-HT receptor site, and further functional assays and/or animal experiments are required for this determination. Furthermore, the pharmacological consequences of the observed 5-HT binding in vitro, if any, may be entirely regiospecific within the CNS. It is intriguing that, although the majority of published research on ADHD, its pathogenesis, and its pharmacotherapy with MPH has focused on DA and/or NE transport or receptor binding, there is an existing literature supporting at least a partial role for 5-HT in ADHD and the pharmacological activity of medications used to treat ADHD successfully, including MPH (Gainetdinov et al. 1999; Quist and Kennedy 2001; Davids et al. 2002b; Quist et al. 2003) . Additionally, molecular genetic studies have identified several candidate 5-HT-related genes that may be implicated in the pathogenesis of ADHD (see Faraone 2005) .
In conclusion, this exploratory investigation found in vitro pharmacological evidence for a potential multimodal effect of MPH on neurotransmitter sites likely to be involved in producing therapeutic effects in the treatment of ADHD. The most prominent effect, as measured by NET binding and cellular uptake studies, appeared to implicate NE as a key neurotransmitter in MPH effects with somewhat lesser effects on DA. In both instances, d-MPH accounted for essentially all of the activity. Binding affinity was also apparent at two of sixteen 5-HT subreceptor binding sites assessed; 5-HT 1A and 5-HT 2B . Further studies are necessary to determine the nature of receptor binding at these sites (i.e., agonist vs antagonist), and to relate binding affinity to any potential behavioral effects of administered 
